
Bernd Heinrich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7197076/publications.pdf Version: 2024-02-01



REDNO HEINDICH

#	Article	IF	CITATIONS
1	Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 2018, 360, .	6.0	931
2	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cellular and Molecular Immunology, 2021, 18, 112-127.	4.8	159
3	Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 536-554.	8.2	158
4	Combined locoregional-immunotherapy for liver cancer. Journal of Hepatology, 2019, 70, 999-1007.	1.8	146
5	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discovery, 2021, 11, 1248-1267.	7.7	117
6	Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 449-457.	1.8	102
7	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2018, 67, 1305-1315.	2.0	93
8	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death and Disease, 2018, 9, 620.	2.7	90
9	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. European Journal of Cancer, 2016, 59, 160-170.	1.3	78
10	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1145-1154.	1.8	76
11	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. Journal of Hepatology, 2021, 74, 700-715.	1.8	60
12	The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut, 2022, 71, 1161-1175.	6.1	60
13	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. Journal of Hepatology, 2022, 77, 748-760.	1.8	57
14	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
15	Steatohepatitis Impairs T-cell–Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 2021, 160, 331-345.e6.	0.6	46
16	Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. OncoTargets and Therapy, 2017, Volume 10, 2389-2401.	1.0	36
17	Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response. Cancer Immunology Research, 2021, 9, 1024-1034.	1.6	29
18	Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1. Frontiers in Oncology, 2014, 4, 92.	1.3	22

Bernd Heinrich

#	Article	IF	CITATIONS
19	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. OncoTargets and Therapy, 2013, 6, 1119.	1.0	16
20	Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1166-1178.	2.3	15
21	Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. Methods and Protocols, 2018, 1, 21.	0.9	14
22	NAFLD indirectly impairs antigen-specific CD8+ TÂcell immunity against liver cancer in mice. IScience, 2022, 25, 103847.	1.9	12
23	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. IScience, 2021, 24, 101990.	1.9	11
24	Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterology Journal, 2020, 8, 444-452.	1.6	9
25	Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	4
26	Development of shellfish allergy after exposure to dual immune checkpoint blockade. Hepatic Oncology, 2018, 5, HEP02.	4.2	3
27	Plasticity of Innate Lymphoid Cells in Cancer. Frontiers in Immunology, 2022, 13, .	2.2	1
28	Innate lymphoid cells at the crossroadsÂof innate and adaptive immunity. Hepatology, 2022, 76, 903-905.	3.6	0